Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging

James P.B. O’Connor,1,2 Richard A.D. Carano,3 Andrew R. Clamp,2 Jed Ross,3 Calvin C.K. Ho,3 Alan Jackson,1 Geoff J.M. Parker,1 Chris J. Rose,1 Franklin V. Peale,4 Michel Friesenhahn,5 Claire L. Mitchell,1,2 Yvonne Watson,1 Caleb Roberts,1 Lynn Hope,2 Sue Cheung,1 Hani Bou Reslan,3 Mary Ann T. Go,6 Glenn J. Pacheco,6 Xiumin Wu,7 Tim C. Cao,3 Sarajane Ross,6 Giovanni A. Buonaccorsi,1 Karen Davies,1 Jurjees Hasan,2 Paula Thornton,2 Olivia del Puerto,8 Napoleone Ferrara,7 Nicholas van Bruggen,3 and Gordon C. Jayson2

Abstract

Purpose: Little is known concerning the onset, duration, and magnitude of direct therapeu tic effects of anti–vascular endothelial growth factor (VEGF) therapies. Such knowledge would help guide the rational development of targeted therapeutics from bench to bedside and optimize use of imaging technologies that quantify tumor function in early-phase clinical trials.

Experimental Design: Preclinical studies were done using ex vivo microcomputed tomography and in vivo ultrasound imaging to characterize tumor vasculature in a human HM-7 colorectal xenograft model treated with the anti-VEGF antibody G6-31. Clinical evaluation was by quantitative magnetic resonance imaging in 10 patients with metastatic colorectal cancer treated with bevacizumab.

Results: Microcomputed tomography experiments showed reduction in perfused vessels within 24 to 48 h of G6-31 drug administration (P ≤ 0.005). Ultrasound imaging confirmed reduced tumor blood volume within the same time frame (P = 0.048). Consistent with the preclinical results, reductions in enhancing fraction and fractional plasma volume were detected in patient colorectal cancer metastases within 48 h after a single dose of bevacizumab that persisted throughout one cycle of therapy. These effects were followed by resolution of edema (P = 0.0023) and tumor shrinkage in 9 of 26 tumors at day 12.

Conclusion: These data suggest that VEGF-specific inhibition induces rapid structural and functional effects with downstream significant antitumor activity within one cycle of therapy. This finding has important implications for the design of early-phase clinical trials that incorporate physiologic imaging. The study shows how animal data help interpret clinical imaging data, an important step toward the validation of image biomarkers of tumor structure and function. (Clin Cancer Res 2009;15(21):6674–82)

Vascular endothelial growth factor (VEGF) plays a crucial role in angiogenesis by promoting endothelial cell proliferation, migration, and vascular permeability. These effects enable tumor growth and survival (1, 2). Consequently, VEGF signaling has become an important target in drug development and has led to Food and Drug Administration approval of drugs that target either VEGF or the VEGF receptor (3, 4). In particular, phase III trials of the humanized anti-VEGF monoclonal antibody bevacizumab (Avastin; Genentech) in combination with cytotoxic chemotherapeutics have shown improved overall survival in patients with metastatic colorectal cancer (CRC; ref. 5) and non–small cell lung cancer (6). Improved

Authors’ Affiliations: 1Imaging Science and Biomedical Engineering, School of Cancer and Imaging Sciences, University of Manchester and 2Cancer Research UK and University of Manchester Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; 3Biomedical Imaging Group, Department of Tumor Biology and Angiogenesis, Departments of 4Pathology, 5Biostatistics, 6Translational Oncology and 7Ferrara Laboratory, Genentech, Inc., South San Francisco, California; and 8Roche Products Limited, Hertfordshire, United Kingdom

Received 3/26/09; revised 8/4/09; accepted 8/10/09; published OnlineFirst 10/27/09.

Grant support: Roche Products Ltd. and by Cancer Research UK grant C19221/A6086 (J.P.B. O’Connor).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

J.P.B. O’Connor, R.A.D. Carano, and A.R. Clamp contributed equally to this work.

Requests for reprints: James O’Connor, Imaging Science and Biomedical Engineering, School of Cancer and Imaging Sciences, University of Manchester, Oxford Road, Manchester, M13 9PT, United Kingdom. Phone: 44-161-275-0040; Fax: 44-161-275-0003; E-mail: james.o’connor@manchester.ac.uk.

© 2009 American Association for Cancer Research.

doi:10.1158/1078-0432.CCR-09-0731

Downloaded from clincancerres.aacrjournals.org on April 14, 2017. © 2009 American Association for Cancer Research.
progression-free survival has also been reported in metastatic breast cancer (7).

These reports have led to rapid adoption of anti-VEGF therapies into clinical practice. This has been accompanied by interest in developing noninvasive image biomarkers that are sensitive to changes in the tumor microvasculature, because anti-VEGF therapies typically exhibit cytostatic rather than cytotoxic effects on tumor growth with little reduction in tumor size (8, 9). In particular, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has been incorporated in early-phase clinical trials of anti-VEGF antibody therapy (10, 11), tyrosine kinase inhibitors (TKI; refs. 12, 13) and vascular disrupting agents (VDA; ref. 14), to provide pharmacodynamic end points to assess drug activity.

At present, relatively little is known about the onset, magnitude, duration and temporal evolution of anti-VEGF therapy antivascular effects. Such information should have important implications for the rational development of targeted therapeutics and for the optimal design of future clinical trials incorporating physiologic imaging end points (15, 16). To explore this issue, we performed clinical studies to evaluate the effects of bevacizumab in CRC patients with liver metastases using DCE-MRI.

Corroborative data were provided from preclinical studies using X-ray microcomputed tomography (micro-CT) angiography, DCE ultrasound (DCE-US) and histology in a CRC murine HM-7 xenograft model. The HM-7 model was chosen because of the strong response (based on tumor size) of this tumor cell line to anti-VEGF therapy and with the goal to better understand the vascular effects of a highly responsive tumor. Preclinical studies were done with G6-31, a novel antibody to VEGF-A. G6-31 is a high-affinity antibody to both murine and human VEGF-A, which has ~10 times greater binding affinity to human VEGF than A4.6.1 or the humanized version (bevacizumab). G6-31 has been shown to provide greater efficacy in preclinical xenograft models (including HM-7) than bevacizumab due to its ability to bind both tumor (human) and stromal (mouse) VEGF (17).

The primary aim of this study was to define the temporal evolution of antivascular effects induced during a single cycle of anti-VEGF monotherapy. The secondary aim was to investigate whether cross-species imaging could provide insight into drug mechanism of action.

Materials and Methods

Preclinical studies

Animal preparation. The Genentech, Inc. Association for Assessment of Accreditation of Laboratory Animal Care-accredited review board approved all animal procedures. HM-7 human colon cancer cells (5 × 10⁶ cells per animal) were implanted s.c. in the flanks of female athymic nude mice (Charles River Laboratory). Mice weighed between 20 to 25 grams. Tumors were grown to between 100 and 300 mm³ (where volume = 0.5 × length × width³) at which point animals were enrolled into study.

Micro-CT angiography time course study. Forty-one animals were randomized into two treatment groups. Animals received 5 mg/kg i.v. (90-min study) or i.p. (24- and 48-h studies) injection of either G6-31 or isotype control antibody. I.v. dosing was used for the 90-min study to maximize exposure over the 90 min of the experiment. Micro-CT angiography was used to measure vascular density in murine HM-7 xenografts, performed after animals were sacrificed at three time points: 90 min (G6-31, n = 6; control, n = 6), 24 h (G6-31, n = 4; control, n = 4), and 48 h (G6-31, n = 10; control, n = 11).

The micro-CT angiography methodology used in this study has been described previously in detail (18). In brief, animals were perfused with MICROFIL lead chromate latex immediately after sacrifice. The infused latex mixture was allowed to polymerize at room temperature for 60 min before tissue harvest. Dissected tumors were immersed in 10% neutral buffered formalin.

Tumors were then imaged with a μCT40 (SCANCO Medical) system (tube, 45 kV; current, 177 μA; integration time, 450 ms; isotropic resolution, 16 μm). An intensity threshold of 1,195 Hounsfield Units (HU) and morphologic filtering (erosion and dilation) were applied to the volumetric micro-CT image data to extract the vascular volume (VV). Tumor volume (TV) was extracted from the background in similar fashion with an intensity threshold of -8 Hounsfield Units. Vascular density was calculated as the ratio of vascular volume to TV. Vascular and tumor intensity thresholds were determined by visual inspection of the segmentation results from a separate set of samples. Computations were done by an in-house image analysis algorithm written in C++ and Python that used the AVW image processing software library (AnalyzeDirect, Inc.). Three-dimensional surface renderings were created from the micro-CT data with the use of Analyze 7.0 (AnalyzeDirect, Inc.).

Tumors were then evaluated by MECA-32 histology. Formalin-fixed, paraffin-embedded tissue sections were deparaffinized and pretreated with Target Retrieval (Dako) at 99°C for 20 min. Quenching of endogenous peroxidase activity and blocking of endogenous biotin (Vector) followed at room temperature. Sections were further blocked for 30 min with 10% normal rabbit serum in PBS with 3% bovine serum albumin. Tissue sections were then incubated with rat anti-mouse panendothelial cell antigen, clone MECA-32 at 2 μg/mL (BD Biosciences) for 60 min, biotinylated rabbit anti-rat at 2.5 μg/mL (Vector) for 30 min, ABC reagent (Vector) for 30 min, followed by a 5-min incubation in Metal Enhanced DAB (Pierce). Sections were counterstained with Mayer’s hematoxylin. MECA-32-stained sections were analyzed with an Ariol SL-50 slide scanning platform (Applied Imaging), using a x10 objective to quantify vascular density. Tumor regions were identified and outlined manually. Pixel color corresponding to MECA-32 staining were defined using a customized Metamorph software (Molecular Devices) algorithm and vascular area was measured and normalized to tumor area.

DCE-US and micro-CT angiography study. Thirty-four animals were randomized into two treatment groups, control and G6-31, as follows: 4 h (G6-31, n = 13; control, n = 13) and 48 h (G6-31, n = 6; control, n = 6). Pretreatment ultrasound imaging was done to measure TV. Animals
then received 5 mg/kg i.v. (4-h study) or i.p. (48-h study) injection of either G6-31 or isotype control antibody. Intravenous dosing was used for the 4-h study to maximize exposure over the 4 h of the experiment. Ultrasound imaging was repeated 4 or 48 h posttreatment, after which animals were sacrificed and micro-CT angiography was done.

Mice were anesthetized using 2% isoflurane delivered in medical air at 1 L/s flow rate and placed supine on a dedicated small animal holding system (VisualSonics, Inc.). Temperature was maintained at 37°C with a heated imaging platform. Body temperature and heart rate were monitored (THM 150, Indus Instruments). Imaging was done with a Vevo 770 micro-imaging system (VisualSonics, Inc.) using a single-element ultrasound transducer (center frequency, 40 MHz; focal length, 6 mm; axial resolution, 40 μm; lateral resolution, 100 μm).

Microbubble ultrasound contrast agent (Definity, Bristol-Meyers Squibb Medical Imaging, Inc.) was administered as an i.v. bolus injection of 20 μL through a jugular vein puncture followed by a 20-μL saline flush. Single-slice B mode imaging was done (center frequency, 40 MHz; 50% power; axial resolution, 40 μm; lateral resolution, 100 μm; 20 frames per second). The ultrasound probe was aligned perpendicular to the animal and the tumor center was determined. Eight hundred frames were acquired for first-pass kinetics analysis, the first 20 of which were acquired before contrast agent injection. These processes were done in three planes (located within 1 mm of one another) and mean tumor area was calculated.

First-pass kinetics analysis of the signal intensity-time curve was used to measure relative blood volume (rBV) and vascular transit time for each pixel (19). Relative blood flow (rBF) was obtained for each pixel, where rBF = rBV/vascular transit time. A lower limit perfusion threshold was determined from regions within the tumor that showed no enhancement after contrast agent administration. Mean rBV, rBF, and vascular transit time were determined for the perfused tumor tissue. Mean tumor area was calculated as the average area in three tumor planes: the center and ±1 mm from the center of the tumor. Each tumor area measurement was calculated from an average of 15 B-mode (precontrast) frames acquired before injection of microbubbles. The averaging of the precontrast images provided a high SNR image. The border of the tumor area was traced to exclude the skin, subcutaneous fat and muscle.

Clinical study

Study design and patient selection. Ethical approval was obtained from the Local Research Ethics Committee. Regulatory approval was granted by the UK Medicines and Healthcare Products Regulatory Agency. Ten patients with liver metastases from histology-proven primary epithelial CRC and no previous cytotoxic chemotherapy exposure were recruited in an open label study. Written informed consent was obtained from all patients, and clinical data were collected from medical records. All patients had a serum carcinoembryonic antigen (CEA) level of 

Fig. 1. Ex vivo evidence for rapid antivascular effects of G6-31. A, change in vascular density (VV/TV), as measured by micro-CT at 90 min, 24 h, and 48 h in control animals and those treated with the anti-VEGF antibody G6-31. B, representative micro-CT angiographic data for each treatment group at 90 min and at 24 and 48 h. Extracted vascular network (red) and entire tumor (gray) are shown. C, histologic sections stained with MECA-32 for corresponding time points. Note that the brown intravascular pigment is micro-CT lead chromate contrast agent, which only partially fills vessel lumens after histologic processing. Vessel area was measured by assessing 3,3′-diaminobenzidine-stained endothelium at the vessel perimeter. See Supplementary Fig. S1 for the corresponding segmented images.
consent was obtained. Patients ages ≥18 y, with an Eastern Cooperative Oncology Group score between 0 and 2, and life expectancy of at least 3 mo were eligible. All patients had at least one measurable lesion of ≥2 cm present on three or more adjacent MRI slices and had no previous treatment with VEGF inhibitors or cytotoxic chemotherapy, or contraindications to VEGF inhibitors.

Patients received single agent 10 mg/kg bevacizumab (cycle 1) followed every 2 wk by 10 mg/kg bevacizumab plus FOLFOX-6 (oxaloplatin/S-fluorouracil/leucovorin) for up to 6 mo (cycles 2-13). MRI scans were done during cycle 1 only, twice at baseline to establish parameter repeatability and then at 4 and 48 h posttreatment and days 8 and 12.

MRI data acquisition and analysis. Data were acquired on a 1.5T Philips Intera system (Philips Medical Systems). Anatomic precontrast T₁- and T₂-weighted images were done. Next, 75 axial T₁-weighted fast field echo volumes were consecutively-acquired every 4.97 s for a total of 6 min 13 s (TR, 4.0 ms; TE, 0.82 ms; α = 20°; one signal average; FOV, 375 mm × 375 mm; matrix, 128 × 128, 25 slices) following calculation baseline of T₁ (α = 2°/10°/20°; 4 signal averages; identical TR, TE, imaging matrix). Omniscan (0.1 mmol/kg; Amersham Health) was administered i.v. through a Spectris MR (Medrad, Inc) power injector at 3 m/s on the sixth dynamic time point. Slice thickness was 4 mm for small target lesions or 8 mm for larger lesions (superior-inferior coverage of 100 or 200 mm). Finally, a postcontrast T₁-weighted image was acquired.

Regions of interest were defined in three-dimensions on the spatially coregistered high resolution T₁- and T₂-weighted volumes to encompass the entire tumor of interest. Whole TV was measured for each lesion. Voxels whose precontrast and postcontrast agent time series had significantly different distributions (where P < 0.05 on Mann-Whitney Wilcoxon rank-sum test) were classified as enhancing. The enhancing fraction (Eₓ) was calculated by dividing the number of enhancing voxels by the total number of tumor voxels.

DCE-MRI data were analyzed using in-house software. Tumor Tₑ was calculated using the known relationship between the spoiled gradient echo signal, TR, flip angle, and Tₑ. An arterial input function was measured where possible; alternatively, a population-derived function was applied (20) and the kinetic model parameters volume transfer constant (Kₑ), fractional volume of the extravascular extracellular space (vₑ), and fractional blood plasma volume (vₑ) were derived using the extended Tofts version of the Kety model. The model free parameter initial area under the gadolinium contrast agent concentration time curve at 60 s (IAUC₆₀) was also calculated (21). All parameters were calculated voxel-by-voxel. Median values of Tₑ, Kₑ, vₑ, and IAUC₆₀ and the mean vₑ were determined from the enhancing portion of each tumor regions of interest.

Statistical analysis
In the animal studies, statistical analysis was done with JMP statistical software package (SAS Institute, Inc.). Group comparisons for micro-CT and ultrasound metrics were evaluated with Student’s t test. P values of <0.05 were considered significant.

In the clinical study, statistical analysis was done using R (version 2.7.0). DCE-MRI data were analyzed on the logarithmically transformed scale. Repeatability was assessed using the replicate measurements available at baseline across patients. Reductions relative to baseline were based on results from random effects models where lesion-to-lesion effects within patients were included as random effects; separate random effects models were fit for each time point during treatment (4, 48 h, 8, and 12 d). Antilogs of the mean differences between baseline and time points during treatment were calculated to obtain relative changes from geomean baseline values expressed as percentages. Due to the large number of parameters analyzed, P values of <0.01 were considered statistically significant. All P values are two tailed and were not formally adjusted for multiple comparisons.

Results
Ex vivo evidence for rapid G6-31 antivasular effects. Vascular density was measured using ex vivo micro-CT angiography along with corroborative histologic measurements. We found statistically significant reductions in vascular density following G6-31 treatment compared with control animals at both 24 h (G6-31 treated, 3.6 ± 0.6%; control, 7.7 ± 1.8%; P = 0.005) and 48 h (G6-31 treated, 3.2 ± 1.1%; control, 6.0 ± 1.9%; P = 0.0005; Fig. 1A). Three dimensional micro-CT renderings exhibited a greatest reduction in central (core) tumor vasculature and a more modest effect in the peripheral vessels, which include coopted host vasculature (Fig. 1B).

MECA-32 histologic analysis of the same animals confirmed significant reduction in vascular density to 40% to 50% of the levels observed in the control group at both 24 h (G6-31 treated, 1.8 ± 0.2%; control, 4.6 ± 1.9%; P = 0.032) and 48 h (G6-31 treated, 2.2 ± 0.7%; control, 4.3 ± 0.9%; P = 0.00001; Supplementary Figure and Fig. 1C). Vascular density estimates, measured by Micro-CT and MECA-32 staining, were not significantly different from the control group at 90 minutes after G6-31 administration.

In vivo evidence for rapid G6-31 antivasular effects. DCE-US studies were done with the same animal model to determine if the above results were detectable in vivo. Subsequent ex vivo micro-CT measurements were also obtained. No differences were found in ultrasound estimates of rBV and rBF, or the micro-CT measurement of vascular density obtained 4 h after G6-31 administration.

Tumor rBV was reduced in the G6-31–treated group relative to the control group at 48 h posttreatment (G6-31 treated,
17.2 ± 9.9%; control, 6.3 ± 6.4%; P = 0.048). Tumor rBF exhibited a trend toward reduction in the G6-31–treated group at 48 h (G6-31 treated, 18.4 ± 13.3%; control, 7.9 ± 4.8%; P = 0.0991) that was not statistically significant (Fig. 2A). Micro-CT angiography analysis was done following animal sacrifice and showed significant reductions in microvascular density for the G6-31–treated tumors exhibited a heterogeneous spatial pattern consistent with the vessel loss observed in the micro-CT data (Fig. 2B, bottom right). These ultrasound data, along with the results from the micro-CT angiography time course study, show that a reduction in tumor rBV accompanies vessel loss following treatment with G6-31, suggesting that rBV is sensitive to structural change within tumor vasculature following antivascular therapy.

Mean tumor area was significantly increased in the control group compared with animals treated with G6-31 at both 4 h (G6-31 treated, 0.27 ± 4.7%; control, 5.1 ± 4.4%; P = 0.0125) and 48 h (G6-31 treated, 37.3 ± 11.6%; control, 70.4 ± 16.0%; P = 0.00001). These data suggest that structural changes in the tumor vasculature measured by endothelial cell staining, micro-CT, and ultrasound lead to rapid growth stabilization. The detection of tumor growth suppression at 4 h in the absence of statistically significant microvascular changes may reflect the limitations of micro-CT and ultrasound in detecting small vascular differences that were more pronounced at 24 to 48 h.

Clinical evidence for rapid antivascular effects induced by bevacizumab in human CRC metastases. Reductions in \( v_p \) and \( E_\text{T} \) were detected throughout the cycle of bevacizumab administration. However, reductions in \( v_p \) and \( E_\text{T} \) that remained suppressed to day 8. These reductions were not sustained at day 12 (Table 1; Figs. 3 and 4C), suggesting that \( K_{\text{trans}} \) and \( \text{IAUC}_{60} \) were sensitive to structural changes induced by antivascular therapy and are useful parameters for interpreting DCE imaging. Parameter within-subject coefficient of variation was 7.1% for \( v_p \) and 15.4% for \( K_{\text{trans}} \). A hyperacute hemodynamic response at 4 h in the human CRC metastases that differs from the sustained reduction (48 h through to day 12) in blood plasma volume that accompanied later vessel loss. A hyperacute response was not observed in the HM-7 xenograft studies. One possible explanation for the lack of a hyperacute hemodynamic response in the tumor xenograft model is that the HM-7 tumor vasculature is highly immature and lacks significant smooth muscle coverage. I.v. dosing was used in these acute time point studies to maximize exposure over the short time period. It is unlikely that the negative results obtained at 90 minutes and 4 h could be due to the different route of administration because steady-state levels would be reached sooner with i.v. administration.

Bevacizumab induces change in \( K_{\text{trans}} \) and \( \text{IAUC}_{60} \) in human CRC metastases. We found statistically significant decrease in median \( K_{\text{trans}} \) at 4 h (P = 0.0012) following bevacizumab therapy that remained suppressed to day 8. These reductions were not sustained at day 12 (Table 1; Figs. 3 and 4C), suggesting that \( K_{\text{trans}} \) is more sensitive to functional changes in the

---

**Table 1. Percentage change in \( E_\text{T} \) DCE-MRI parameters, longitudinal relaxation time, and whole TV measured from baseline to four posttreatment time points (4 and 48 h, and days 8 and 12)**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>BL to 4 h</th>
<th>P</th>
<th>BL to 48 h</th>
<th>BL to day 8</th>
<th>BL to day 12</th>
</tr>
</thead>
<tbody>
<tr>
<td>( E_\text{T} )</td>
<td>-7.5</td>
<td>0.0913</td>
<td>-18.1</td>
<td>0.0040</td>
<td>-22.2</td>
</tr>
<tr>
<td>( v_p )</td>
<td>-34.9</td>
<td>0.0086</td>
<td>-35.2</td>
<td>0.0678</td>
<td>-40.9</td>
</tr>
<tr>
<td>( K_{\text{trans}} )</td>
<td>-52.0 to -11.7</td>
<td>-59.5 to 3.6</td>
<td>-25.5</td>
<td>0.0243</td>
<td>-32.0</td>
</tr>
<tr>
<td>( v_p )</td>
<td>-30.8 to -10.5</td>
<td>-42.0 to -4.2</td>
<td>-2.3</td>
<td>0.8704</td>
<td>-18.1</td>
</tr>
<tr>
<td>( T_1 )</td>
<td>-4.0</td>
<td>0.5337</td>
<td>-5.9</td>
<td>0.3132</td>
<td>-13.3</td>
</tr>
<tr>
<td>( \text{WTV} )</td>
<td>-16.3 to 10.1</td>
<td>-16.8 to 6.5</td>
<td>-0.3</td>
<td>0.5374</td>
<td>-14.2</td>
</tr>
<tr>
<td>( v_p )</td>
<td>-30.8 to -10.5</td>
<td>-10.9 to 6.4</td>
<td>-23.5</td>
<td>0.015</td>
<td>-9.9</td>
</tr>
<tr>
<td>( v_p )</td>
<td>-9.0</td>
<td>0.8218</td>
<td>-10.2 to 9.7</td>
<td>0.8704</td>
<td>-27.1 to 11.3</td>
</tr>
</tbody>
</table>

**NOTE:** Mean values of percentage change and 95% confidence intervals are expressed. \( P \) values are two tailed, considered significant when <0.01, and were calculated using the mixed effects model on logarithmically transformed data. Abbreviations: \( T_1 \), longitudinal relaxation time; \( \text{WTV} \), whole TV; BL, baseline.

---

\(^{2}\) F.V. Peale, unpublished observations.
tumor vasculature rather than structural changes. Example parameter maps are shown in Fig. 4C. Change in median $\text{IAUC}_{60}$ mirrored those of $K_{\text{trans}}$ (data not shown).

The timing and magnitude of these changes are in keeping with previous clinical trials of anti-VEGF antibodies (10) and TKI (12, 24, 25). However, changes in $K_{\text{trans}}$ and $\text{IAUC}_{60}$ are difficult to interpret. $\text{IAUC}_{60}$ is relatively easy to calculate and repeatable but is not physiologically specific. $K_{\text{trans}}$ is a composite estimate of both the blood flow and the permeability-surface area product per unit volume of tissue for transendothelial transport between plasma and extravascular space (26). The observed initial reductions in $K_{\text{trans}}$ are, therefore, consistent both with an initial decrease in blood flow and/or a reduction in vessel permeability. This difficulty in interpretation is an important factor when the analysis of DCE imaging data are restricted to physiologically nonspecific parameters.

**Evidence that bevacizumab induces edema resolution and tumor shrinkage.** Reduction in TV was detected across the cohort of 26 tumors by day 12 (Fig. 5A), although this change did not reach statistical significance ($P = 0.0569$). No patients achieved partial response as defined by Response Evaluation Criteria in Solid Tumors. Based on the replicate observations taken at baseline, 95% of ratios of serial measurements of TV are estimated to be between 76.2% and 131.3%. Using these criteria, 9 of 26 tumors (in five different patients) exhibited statistically significant volume reduction (Fig. 5B).

Reductions in TV were accompanied by statistically significant reductions in tumor precontrast $T_1$ from baseline to day 12 ($P = 0.0023$; Figs. 4D and 5A), likely to represent resolution of tumor edema caused by reduced vascular permeability. This mirrors similar rapid resolution of edema observed following inhibition of VEGF with TKI AZD2171 in glioblastoma multiforme (27). Although a small cytotoxic effect secondary to the early antivasculature effects of bevacizumab cannot be discounted, these data support the hypothesis that bevacizumab-induced reduction in vascular permeability and blood flow leads to reduced tumor tissue edema, accompanied by reduction in TV.

**Discussion**

Physiologic imaging can provide detailed quantitative information concerning tumor biology and drug mechanism of action that may help guide the rational development of targeted therapeutics (16). We have presented valuable new information concerning the temporal evolution of antivascular effects induced by anti-VEGF antibodies that has important implications for studies that evaluate antivascular or antiangiogenic agents.

**Insight into drug mechanism of action.** Previous studies have shown rapid reductions in vascular permeability. In one study, Berry et al. (28) found that 24 h after treatment with G6-31, $K_{\text{trans}}$ was reduced 62% in the same HM-7 xenograft model that was used in this article. Our current results show that micro-CT angiography, a technique used previously to characterize normal tissue and tumor vasculature (18), can detect rapid vessel loss in murine HM-7 xenografts within the first 24 h following treatment with G6-31. This is the first study to show that an anti-VEGF therapy can reduce tumor vascular density within such a short time frame. These changes were accompanied by reductions in blood volume, observed at 48 h using DCE-US.

These data (measurements of blood volume and vascular density) reflect structural changes in tumor vasculature following anti-VEGF therapy and help interpret the clinical DCE-MRI data (measurements of fractional blood plasma volume and proportional tumor enhancement) at 48 h after bevacizumab administration in metastatic CRC. Further DCE-MRI data at 8 and 12 days provide evidence that these effects, likely to be structural, are maintained throughout a 2-week cycle of bevacizumab and lead to resolution of tumor edema and decrease in TV.

In distinction, the parameters $K_{\text{trans}}$ and $\text{IAUC}_{60}$ showed transient reductions from baseline values that were lost by the end of the cycle of anti-VEGF therapy. Both $K_{\text{trans}}$ and $\text{IAUC}_{60}$ reflect a combination of blood flow and capillary permeability, suggesting that these parameters are sensitive to transient functional changes in the tumor vasculature and that measurement timing is critical to detect these changes induced by anti-VEGF therapy.

Overall, these data provide evidence that the structural and functional changes induced by anti-VEGF monoclonal antibodies lead to rapid downstream effects in tumor morphology. Growth stabilization was shown within 48 h in murine HM-7 xenografts treated with G6-31, relative to controls. In the clinical data, CRC liver metastases showed statistically significant reduction in $T_1$, consistent with resolution in edema that was accompanied by a trend toward volume reduction across the group of metastases. In 9 of 26 lesions, the volume reduction was statistically significant. Taken together, these data provide cross-species evidence for antivascular effect with anti-VEGF antibodies within 48 h, with resultant rapid resolution of edema and tumor shrinkage.

There are several limitations to this study that qualify the above conclusions. For the preclinical study, a single xenograft model was evaluated by using multiple imaging modalities and time points. The extensive evaluation of a single responsive model does not provide a thorough evaluation of the magnitude of the vascular imaging response as a function of the responsiveness of the tumor. This would require the evaluation of number of additional models that represent a range (including a nonresponder) of responsiveness based on TV. This would likely provide additional insight into the range of the vascular response and answer the question of the state of these vascular imaging parameters in a nonresponding tumor. It would also be of value to evaluate a model of liver metastases, where...
tumors would likely experience a more representative microenvironment to that experienced by clinical CRC liver metastases. Although these are interesting questions, they are beyond the scope of this study, which focused on quantifying the vascular response of a tumor model where there is a potent anti-VEGF response as a means to better understand the vascular changes associated with the positive DCE-MRI response that has been observed in clinical anti-VEGF studies. For the clinical study, the temporal resolution of the DCE-MRI study was not sufficient to obtain independent estimates of blood flow and permeability.

Choice of physiologic imaging biomarkers in clinical trials. Traditional clinical trial assessment of tumor response has relied on codified radiological response criteria (29, 30). In Response Evaluation Criteria in Solid Tumors, a categorical measurement of treatment response is provided where partial response is defined as >30% reduction in the longest diameter of the sum of all marker lesions, which equates to around 65% reduction in TV (31). Using this approach, antivascular and antiangiogenic agents have been considered to induce insignificant changes in tumor size (8). This has stimulated considerable interest in the serial noninvasive evaluation of the tumor microenvironment in early-phase clinical trials of targeted therapeutics.

DCE-MRI and DCE-CT have been used to estimate tumor blood flow, blood volume, and edema and provide pharmacodynamic end points of drug activity in around 30 phase I/II clinical trials of anti-VEGF antibodies, TKI, and VDA. Nearly all of these studies have reported either Ktrans or IAUC60 as primary end points in line with consensus recommendations (32). However, these parameters have equivocal and complex physiologic meanings (9). This study shows the value of using multiparametric analyses that includes tumor T1, Er, and multiple modeled parameter end points that includes vp, rather than Ktrans and/or IAUC60 alone. Such an approach enables changes in both the tumor vascular structure and function to be detected.

This study shows that measuring tumor size may yield important information in studies of some targeted therapeutic agents, when size change is assessed as a continuous (rather than categorical) variable. This finding concurs with previous reports in patients with metastatic renal cell cancer receiving sorafenib (33), suggesting that tumor size should remain an important metric for evaluating drugs that induce changes in blood flow and vascular permeability. In practice, it may be the combination of biomarkers based on tumor size, morphology, and function that provides the most useful evaluation of targeted therapeutics in early-phase clinical development.

Importance of measurement timing in image analysis. We have reported DCE-MRI data that quantify the temporal evolution of the antivascular effects of bevacizumab. To date, imaging studies have neither optimized scan timing nor had sufficient frequency of examination to accurately characterize the pharmacodynamic properties of novel therapies (9, 34).
and at the end of a three week cycle in a DCE-MRI study of inflammatory breast cancer (11).

In this clinical study, we chose imaging time points at 4 and 48 h (consistent with the ex vivo and in vivo animal studies, and with trials of VDA and TKI) and day 12 (bevacizumab has been reported previously to impair blood flow and blood volume at this time in CRC; ref. 36). An additional time point was selected at day 8 because preclinical evidence has suggested that vascular normalization may occur within a week following administration of a VEGF receptor inhibitor (37). Our results show a complex temporal evolution of parameter change that underpins the interaction of tumor biology and drug mechanism of action and shows how pharmacodynamic biomarkers may be used to optimize evaluation of novel therapies (34). These results support the use of detailed physiologic imaging in small phase I/II studies of antivascular and antiangiogenic agents to define the optimum timing and frequency of image acquisition for large phase II and all phase III trials of the same agents, where practical and economical reasons limit the amount of imaging that may be incorporated.

Lack of validation is a major factor that limits wider acceptance and application of physiologic imaging such as DCE-MRI and DCE-CT to clinical studies of antivascular and antiangiogenic compounds. This study highlights the benefits of multimodality imaging in evaluating mechanism of drug action and how animal data using combined imaging and histology may help to interpret clinical imaging techniques. However, considerable further studies are required to validate the physiologic imaging biomarkers described in this study.

**Disclosure of Potential Conflicts of Interest**


**Acknowledgments**

We thank Jeffrey Eastham-Anderson for developing the Metamorph algorithms, managing the histologic imaging, and automated image analysis of MECA-32-stained tumor samples, and Greg Plowman for his comments on the manuscript.

**References**


8. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 2004;22:4442-5


Fig. 5. Evidence for reduction in tumor size with bevacizumab monotherapy. A, temporal evolution of TV reduction and change in longitudinal relaxation time (T1) from baseline through to day 12 in 26 tumors. B, waterfall plots show percentage reduction in TV from baseline size at day 12. Dotted lines, lesions that changed in size by greater than the lower and upper 95% confidence limits of serial parameter ratios.

Rapid anti-VEGF antibody-mediated antivascular effects have been reported in animal models (35), but the temporal evaluation of bevacizumab-induced antivascular effects in humans has not been done previously. In comparable studies, DCE-MRI measurements have been done at around 4 h postdosing to evaluate VDA (14) and around 24 to 48 h posttherapy to evaluate TKI (25, 27). Studies of bevacizumab have limited imaging end points to late time points in the treatment cycle; patients were imaged at 7 to 12 days following two weekly bevacizumab monotherapy in CRC assessed by DCE-CT (36)
Clinical Cancer Research

Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging


Updated version
Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-09-0731

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2009/10/27/1078-0432.CCR-09-0731.DC1
http://clincancerres.aacrjournals.org/content/suppl/2009/11/02/1078-0432.CCR-09-0731.DC2

Cited articles
This article cites 36 articles, 18 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/15/21/6674.full.html#ref-list-1

Citing articles
This article has been cited by 15 HighWire-hosted articles. Access the articles at:
/content/15/21/6674.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.